MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 142 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 1.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,960,167 | -55.1% | 27,117 | -32.3% | 0.00% | -66.7% |
| Q2 2023 | $8,826,677 | +132373.0% | 40,083 | +41.2% | 0.01% | +20.0% |
| Q1 2023 | $6,663 | -99.6% | 28,390 | +19.3% | 0.01% | +400.0% |
| Q3 2022 | $1,497,000 | -6.6% | 23,800 | +6.9% | 0.00% | -33.3% |
| Q2 2022 | $1,602,000 | +112.2% | 22,265 | +193.2% | 0.00% | +200.0% |
| Q1 2022 | $755,000 | -72.7% | 7,594 | -76.7% | 0.00% | -66.7% |
| Q4 2021 | $2,765,000 | +41.6% | 32,568 | +33.5% | 0.00% | +50.0% |
| Q3 2021 | $1,952,000 | +173.8% | 24,400 | +232.4% | 0.00% | +100.0% |
| Q2 2021 | $713,000 | -55.5% | 7,340 | -46.7% | 0.00% | -50.0% |
| Q1 2021 | $1,604,000 | +0.9% | 13,771 | -3.7% | 0.00% | -33.3% |
| Q4 2020 | $1,589,000 | -43.8% | 14,300 | -39.7% | 0.00% | -57.1% |
| Q3 2020 | $2,826,000 | +79.0% | 23,700 | +54.1% | 0.01% | +40.0% |
| Q2 2020 | $1,579,000 | +583.5% | 15,375 | +365.9% | 0.01% | +400.0% |
| Q1 2020 | $231,000 | – | 3,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tao Capital Management LP | 77,657 | $5,047,000 | 3.31% |
| L1 Capital Pty Ltd | 161,163 | $10,474,000 | 2.05% |
| Avoro Capital Advisors LLC | 1,535,000 | $99,760,000 | 1.84% |
| Affinity Asset Advisors, LLC | 100,000 | $6,499,000 | 1.81% |
| GREAT POINT PARTNERS LLC | 95,500 | $6,207,000 | 1.50% |
| ARMISTICE CAPITAL, LLC | 1,236,000 | $80,328,000 | 1.39% |
| Affinity Asset Advisors, LLC | 75,000 | $4,874,000 | 1.36% |
| MPM BioImpact LLC | 44,747 | $2,908,000 | 0.69% |
| Baker Brothers Advisors | 1,499,213 | $97,434,000 | 0.64% |
| Perceptive Advisors | 331,023 | $21,513,000 | 0.62% |